Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8–7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R)...

Descripción completa

Detalles Bibliográficos
Autores principales: Raderer, M, Hamilton, G, Kurtaran, A, Valencak, J, Haberl, I, Hoffmann, O, Kornek, G V, Vorbeck, F, Hejna, M H L, Virgolini, I, Scheithauer, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362412/
https://www.ncbi.nlm.nih.gov/pubmed/10027326
http://dx.doi.org/10.1038/sj.bjc.6690084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362412/
https://www.ncbi.nlm.nih.gov/pubmed/10027326
http://dx.doi.org/10.1038/sj.bjc.6690084

Ejemplares similares